At a glance
ClinicalIndex Comparison RecordN/ACompleted· 97 enrolled
Drug / intervention
Intranasal Lacrimal Neurostimulator (Oculeve)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single-Arm, Multicenter, Open-Label Study to Evaluate the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Participants With Aqueous Tear Deficient Dry Eye
In Brief
A clinical study evaluating Intranasal Lacrimal Neurostimulator (Oculeve) for Dry Eye Syndromes and Keratoconjunctivitis Sicca. Completed, enrolled 97 participants across 3 sites.
Detailed Summary
In this study, the safety and effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator after 180 days of use in participants with aqueous tear deficiency will be evaluated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes, Keratoconjunctivitis Sicca
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartAug 2015
Primary CompletionApr 2016
TodayJul 2026
First PostedAug 18, 2015
Enrollment StartAug 31, 2015
Primary CompletionApr 30, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.9 years ago
Interventions
Intranasal Lacrimal Neurostimulator (Oculeve)device
Neurostimulation device